Stella to Acquire Some of Field Trip's Psychedelics Therapy Clinics

Stella also plans to open a new treatment clinic in Irvine, California.

Mental health provider Stella, which already offers ketamine-assisted therapies for patients, is expanding its U.S. footprint with the acquisition of some of the treatment clinics run by four-year-old psychedelics startup Field Trip Health & Wellness Ltd. (OTC: FTHWF) (TSX-V: FTHW).

Stella announced in a press release that it will acquire the U.S. assets of Field Trip – including facilities in New York and Washington, D.C. – for an undisclosed sum, though Stella noted that the acquisition follows a $7 million fundraising round it recently completed.

“With the acquisition of Field Trip’s assets, we’re offering patients data-backed treatments that align with our industry leading standards,” Philippe Sanchez, CEO of Stella, said in the release. “By combining our collective expertise, we’re excited to pioneer innovative therapies to shape the future of mental health treatment.”

Stella also plans to open a new treatment clinic in Irvine, California, following the recent addition of a clinic in Chicago.

It also is bringing aboard two former Field Trip executives: former president Mujeeb Jafferi and Amardeep Manhas.

“Ketamine protocols are among the most important breakthroughs for mental health, and we’re excited to integrate our years of clinical research and patient outcomes with Stella’s DSR protocol and psychotherapy,” Jafferi said in the release.

The deal will leave Field Trip with ketamine clinics in Toronto and Vancouver, after the company shuttered five of its clinics in April and paid a third-party consultant before that in an attempt to find a financial way to stay afloat.

It’s a far cry from the plans it announced in a Forbes article, in which the Canada-based business said it planned to list on the Nasdaq and have 21 clinics open by the end of 2021.

Field Trip posted a C$28.7 million loss for the three quarters that ended Dec. 31, 2022, its most recent financial filing with the Securities and Exchange Commission, and reported at the time that it had “not yet achieved profitable operations.”

John Schroyer

John Schroyer has been a reporter since 2006, initially with a focus on politics, and covered the 2012 Colorado campaign to legalize marijuana. He has written about the cannabis industry specifically since 2014, after being on hand for the first-ever legal cannabis sales on New Year’s Day that year in Denver. John has covered subsequent marijuana market launches in California and Illinois, has written about every aspect of the marijuana trade, and was part of the team that built the cannabis industry’s first-ever trade show, MJBizCon. He joined Green Market Report in 2022.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.